Domperidone Should Not Be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders

Benoît Drolet(Hôpital du Saint-Sacrement), Jacques Turgeon(Unknown), Pascal Daleau(Hôpital du Saint-Sacrement), Guy Rousseau(Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal), René Cardinal(Hôpital du Saint-Sacrement)
Circulation
October 17, 2000
10.1161/01.cir.102.16.1883
Cited by 164

Related Papers

Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
|Pharmaceutics|2020|237
The Role of Gut Microbiota on Cholesterol Metabolism in Atherosclerosis
|International Journal of Molecular Sciences|2021|200
Prevalence and Risk of Potential Cytochrome P450–Mediated Drug-Drug Interactions in Older Hospitalized Patients with Polypharmacy
|Annals of Pharmacotherapy|2013|186
Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
|PubMed|1999|177
Block of the Rapid Component of the Delayed Rectifier Potassium Current by the Prokinetic Agent Cisapride Underlies Drug-Related Lengthening of the QT Interval
|Circulation|1998|161